Pimavanserin: Completed Phase III enrollment

Acadia completed enrollment of 198 patients in the double-blind, placebo-controlled, North American Phase III (-020 Study) trial evaluating once-daily 40 mg oral pimavanserin for 6 weeks as adjunct to...